title: MR imaging in nelarabine-induced myelopathy.
abstract: Nelarabine is one of the newer and novel drugs approved by the USA Food and Drug Administration for treatment of relapsed and resistant acute lymphoblastic leukemia. Although there are a few accounts of the neurologic toxicity of nelarabine in the oncological literature, it has never been discussed from a radiologic stand point to our knowledge. We describe a case of nelarabine-induced myelopathy and review the existing literature in an attempt to characterize the MRI features helpful in making an early diagnosis of this elusive entity.
authors.affiliation: Section of Neuroradiology, Department of Radiology, Rush University Medical Center, Chicago, IL 60612, USA. Electronic address: duasum@gmail.com.
authors.forename: Sumeet G
authors.initials: SG
authors.lastname: Dua
authors.affiliation: Section of Neuroradiology, Department of Radiology, Rush University Medical Center, Chicago, IL 60612, USA.
authors.forename: Miral D
authors.initials: MD
authors.lastname: Jhaveri
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001087:Arabinonucleosides / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D059906:Neuroimaging / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D001087:Arabinonucleosides; C104457:nelarabine
keywords: Dorsal column; Myelopathy; Nelarabine; Neurotoxicity; Spinal cord